HRP20171853T1 - Sulfatne soli kao ubrzivači vremena prolaska - Google Patents
Sulfatne soli kao ubrzivači vremena prolaska Download PDFInfo
- Publication number
- HRP20171853T1 HRP20171853T1 HRP20171853TT HRP20171853T HRP20171853T1 HR P20171853 T1 HRP20171853 T1 HR P20171853T1 HR P20171853T T HRP20171853T T HR P20171853TT HR P20171853 T HRP20171853 T HR P20171853T HR P20171853 T1 HRP20171853 T1 HR P20171853T1
- Authority
- HR
- Croatia
- Prior art keywords
- sulfate
- oral
- patient
- sulfate solution
- capsule endoscope
- Prior art date
Links
- 150000003467 sulfuric acid derivatives Chemical class 0.000 title claims 5
- 239000003623 enhancer Substances 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 32
- 239000002775 capsule Substances 0.000 claims 19
- 210000005095 gastrointestinal system Anatomy 0.000 claims 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 4
- 238000001839 endoscopy Methods 0.000 claims 4
- 229910052920 inorganic sulfate Inorganic materials 0.000 claims 4
- 239000008141 laxative Substances 0.000 claims 4
- 230000002475 laxative effect Effects 0.000 claims 4
- 239000011777 magnesium Substances 0.000 claims 4
- 229910052749 magnesium Inorganic materials 0.000 claims 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims 4
- 230000003204 osmotic effect Effects 0.000 claims 4
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims 4
- 239000011591 potassium Substances 0.000 claims 4
- 229910052700 potassium Inorganic materials 0.000 claims 4
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims 4
- 229910052939 potassium sulfate Inorganic materials 0.000 claims 4
- 235000011151 potassium sulphates Nutrition 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 4
- 235000011152 sodium sulphate Nutrition 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000014997 Crohn colitis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002052 colonoscopy Methods 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
- A61B1/041—Capsule endoscopes for imaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Photoreceptors In Electrophotography (AREA)
Claims (15)
1. Upotreba oralne otopine sulfata, naznačena time što je namijenjena pripremi gastrointestinalnog sustava pacijenta za pregled unutrašnjosti gastrointestinalnog sustava pacijenta kapsulom endoskopijom,
gdje oralnu otopinu sulfata treba primijeniti na pacijentu u količini koja djelotvorno prazni gastrointestinalni sustav pacijenta od njegovog sadržaja i čisti gastrointestinalni sustav, i
gdje je oralna otopina sulfata ubrzivač vremena prolaska, sadrži natrijev sulfat, kalijev sulfat, te magnezijev sulfat, sadrži otprilike 0,0096 g/ml do otprilike 0,50 g/ml sulfata u obliku anorganske sulfatne soli, te ne sadrži fosfatnu sol.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što oralna otopina sulfata sadrži otprilike 0,0095 g/ml do otprilike 0,038 g/ml natrija, otprilike 0,002 g/ml do otprilike 0,009 g/ml kalija, otprilike 0,0005 g/ml do otprilike 0,05 g/ml magnezija, te otprilike 0,02 g/ml do otprilike 0,1 g/ml sulfata.
3. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što oralna otopina sulfata sadrži otprilike 0,022 g/ml natrija, otprilike 0,005 g/ml kalija, otprilike 0,001 g/ml magnezija, te otprilike 0,07 g/ml sulfata.
4. Upotreba u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačena time što treba primijeniti otprilike 15 ml do otprilike 1000 ml oralne otopine sulfata.
5. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što oralnu otopinu sulfata treba primijeniti uz kapsularni endoskop, ili
gdje oralnu otopinu sulfata treba primijeniti nakon primjene kapsularnog endoskopa, ili
gdje oralnu otopinu sulfata treba primijeniti više puta prije primjene kapsularnog endoskopa, ili
gdje također treba primijeniti dodatni osmotski laksativ, gdje osmotski laksativ treba primijeniti prije primjene oralne otopine sulfata i kapsularnog endoskopa.
6. Upotreba oralne otopine sulfata, naznačena time što je namijenjena pripremi gastrointestinalnog sustava pacijenta za određivanje izvora, vrste, lokacije, te uzroka gastrointestinalne patološke pojave kod pacijenta,
gdje oralnu otopinu sulfata treba primijeniti na pacijentu koji boluje od patološke pojave radi pripreme gastrointestinalnog sustava pacijenta za kapsularnu kolonoskopiju,
gdje oralnu otopinu sulfata treba primijeniti u količini koja djelotvorno prazni gastrointestinalni sustav i čisti gastrointestinalni sustav, i
gdje otopina sadrži magnezijev sulfat, kalijev sulfat i natrijev sulfat, sadrži otprilike 0,0096 g/ml do 0,50 g/ml sulfata u obliku anorganske sulfatne soli, te ne sadrži fosfatnu sol.
7. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što oralna otopina sulfata sadrži otprilike 0,0095 g/ml do otprilike 0,038 g/ml natrija, otprilike 0,002 g/ml do otprilike 0,009 g/ml kalija, otprilike 0,0005 g/ml do otprilike 0,05 g/ml magnezija, te otprilike 0,02 g/ml do otprilike 0,1 g/ml sulfata.
8. Upotreba u skladu s patentnim zahtjevom 7, naznačena time što oralna otopina sulfata sadrži otprilike 0,022 g/ml natrija, otprilike 0,005 g/ml kalija, otprilike 0,001 g/ml magnezija, te otprilike 0,07 g/ml sulfata.
9. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što 15 ml do 1000 ml oralne otopine sulfata treba primijeniti.
10. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što oralnu otopinu sulfata treba primijeniti uz kapsularni endoskop, ili
gdje oralnu otopinu sulfata treba primijeniti prije primjene kapsularnog endoskopa, ili
gdje oralnu otopina sulfata treba progutati više puta prije primjene kapsularnog endoskopa, ili
gdje također treba primijeniti osmotski laksativ, gdje osmotski laksativ treba primijeniti prije primjene oralne otopine sulfata i kapsularnog endoskopa.
11. Upotreba u skladu s bilo kojim od patentnih zahtjeva 6-10, naznačena time što je gastrointestinalna patološka pojava krvarenje, vrijed, polip, lezija, prekancerozna lezija, rak, divertikulitis, ili upalni poremećaj, uključujući Crohn’ovu bolest, kolitis ili ulcerozni kolitis.
12. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se pregled unutrašnjosti gastrointestinalnog sustava pacijenta kapsulom endoskopijom sastoji u
oralnoj primjeni aktiviranog kapsularnog endoskopa na pacijentu; smještavanju prijemnika za detekciju podataka koje šalje aktivirani kapsularni endoskop dok prolazi kroz unutrašnjost gastrointestinalnog sustava pacijenta; i
analiziranju podataka koje je detektirao prijemnik prije i/ili nakon izbacivanja primijenjenog kapsularnog endoskopa iz debelog crijeva pacijenta.
13. Upotreba u skladu s patentnim zahtjevom 6, naznačena time što se određivanje izvora, vrste, lokacije, te uzroka gastrointestinalne patološke pojave kod pacijenta sastoji u oralnoj primjeni aktiviranog kapsularnog endoskopa na pacijentu;
smještavanju prijemnika koji detektira i sprema podatke koje šalje kapsularni endoskop dok prolazi kroz intestinal sustav pacijenta; i
analiziranju podataka koje je detektirao prijemnik prije i/ili nakon izbacivanja primijenjenog kapsularnog endoskopa iz debelog crijeva pacijenta, gdje podaci ukazuju na vrstu, lokaciju i uzrok patološke pojave.
14. Upotreba oralne otopine sulfata, naznačena time što je namijenjena pripremi gastrointestinalnog sustava pacijenta za kapsularnu endoskopiju,
gdje oralna otopina sulfata sadrži magnezijev sulfat, kalijev sulfat i natrijev sulfat, sadrži otprilike 0,0096 g/ml do 0,50 g/ml sulfata u obliku anorganske sulfatne soli, te ne sadrži fosfatnu sol.
15. Upotreba oralne otopine sulfata, naznačena time što je namijenjena ubrzavanju prolaska kroz gastrointestinalni sustav ili tanko crijevo za kapsularnu endoskopiju,
gdje oralna otopina sulfata sadrži magnezijev sulfat, kalijev sulfat i natrijev sulfat, sadrži otprilike 0,0096 g/ml do 0,50 g/ml sulfata u obliku anorganske sulfatne soli, te ne sadrži fosfatnu sol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475938P | 2011-04-15 | 2011-04-15 | |
| PCT/US2012/033769 WO2012142572A1 (en) | 2011-04-15 | 2012-04-16 | Sulfate salts as transit time enhancer |
| EP12770690.1A EP2696690B1 (en) | 2011-04-15 | 2012-04-16 | Sulfate salts as transit time enhancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171853T1 true HRP20171853T1 (hr) | 2018-02-23 |
Family
ID=47006899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171853TT HRP20171853T1 (hr) | 2011-04-15 | 2017-11-28 | Sulfatne soli kao ubrzivači vremena prolaska |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120265011A1 (hr) |
| EP (2) | EP3292763A1 (hr) |
| JP (4) | JP2014513085A (hr) |
| CY (1) | CY1119693T1 (hr) |
| DK (1) | DK2696690T3 (hr) |
| ES (1) | ES2652490T3 (hr) |
| HK (1) | HK1252468A1 (hr) |
| HR (1) | HRP20171853T1 (hr) |
| HU (1) | HUE037452T2 (hr) |
| LT (1) | LT2696690T (hr) |
| NO (1) | NO2629082T3 (hr) |
| PL (1) | PL2696690T3 (hr) |
| PT (1) | PT2696690T (hr) |
| RS (1) | RS56574B1 (hr) |
| RU (3) | RU2013150330A (hr) |
| SI (1) | SI2696690T1 (hr) |
| WO (1) | WO2012142572A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59667B1 (sr) | 2013-03-15 | 2020-01-31 | Braintree Laboratories Inc | Oralna farmaceutska kompozicija sulfatnih soli u obliku tableta dvostruke primene i postupci njihove upotrebe |
| JP6501923B2 (ja) * | 2015-06-22 | 2019-04-17 | シーティーシー バイオ インコーポレイテッド | 腸管洗浄用の下剤組成物 |
| US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
| KR102111094B1 (ko) * | 2018-06-18 | 2020-05-14 | 주식회사 한국팜비오 | 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물 |
| WO2020121994A1 (ja) * | 2018-12-10 | 2020-06-18 | 日本製薬株式会社 | 医薬組成物 |
| CN110339158B (zh) * | 2019-08-21 | 2020-11-13 | 扬子江药业集团上海海尼药业有限公司 | 一种硫酸钠钾镁口服溶液及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143259A (en) * | 2001-05-20 | 2006-08-01 | Given Imaging Ltd | A method of moving a bone in the colon |
| US6946149B2 (en) * | 2002-04-30 | 2005-09-20 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
| US20050171418A1 (en) * | 2004-01-08 | 2005-08-04 | Tah-Yeong Lin | Capsule endoscopy system |
| CN1284505C (zh) * | 2004-02-28 | 2006-11-15 | 重庆金山科技（集团）有限公司 | 医用无线电胶囊式内窥系统 |
| RU165065U1 (ru) * | 2015-07-01 | 2016-09-27 | Общество с ограниченной ответственностью "Мобильная Информатика" (ООО "Мобильная Информатика") | Беспроводная эндоскопическая капсула |
-
2012
- 2012-04-16 EP EP17194383.0A patent/EP3292763A1/en not_active Withdrawn
- 2012-04-16 RU RU2013150330/14A patent/RU2013150330A/ru unknown
- 2012-04-16 SI SI201231171T patent/SI2696690T1/en unknown
- 2012-04-16 HU HUE12770690A patent/HUE037452T2/hu unknown
- 2012-04-16 PL PL12770690T patent/PL2696690T3/pl unknown
- 2012-04-16 RS RS20171166A patent/RS56574B1/sr unknown
- 2012-04-16 US US13/447,846 patent/US20120265011A1/en not_active Abandoned
- 2012-04-16 EP EP12770690.1A patent/EP2696690B1/en active Active
- 2012-04-16 DK DK12770690.1T patent/DK2696690T3/en active
- 2012-04-16 LT LTEP12770690.1T patent/LT2696690T/lt unknown
- 2012-04-16 WO PCT/US2012/033769 patent/WO2012142572A1/en active Application Filing
- 2012-04-16 ES ES12770690.1T patent/ES2652490T3/es active Active
- 2012-04-16 PT PT127706901T patent/PT2696690T/pt unknown
- 2012-04-16 JP JP2014505397A patent/JP2014513085A/ja active Pending
-
2013
- 2013-02-15 NO NO13155419A patent/NO2629082T3/no unknown
-
2016
- 2016-03-14 JP JP2016049105A patent/JP6189463B2/ja active Active
-
2017
- 2017-01-30 RU RU2017102973A patent/RU2655886C1/ru active
- 2017-08-02 JP JP2017149775A patent/JP6356324B2/ja not_active Expired - Fee Related
- 2017-11-28 HR HRP20171853TT patent/HRP20171853T1/hr unknown
- 2017-12-19 CY CY20171101333T patent/CY1119693T1/el unknown
-
2018
- 2018-05-22 RU RU2018118808A patent/RU2018118808A/ru not_active Application Discontinuation
- 2018-06-13 JP JP2018112399A patent/JP6782281B2/ja active Active
- 2018-09-13 HK HK18111776.7A patent/HK1252468A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012142572A1 (en) | 2012-10-18 |
| ES2652490T3 (es) | 2018-02-02 |
| HK1252468A1 (zh) | 2019-05-24 |
| JP6356324B2 (ja) | 2018-07-11 |
| PL2696690T3 (pl) | 2018-03-30 |
| LT2696690T (lt) | 2018-02-12 |
| RU2655886C1 (ru) | 2018-05-29 |
| RU2018118808A (ru) | 2019-11-25 |
| DK2696690T3 (en) | 2018-01-15 |
| PT2696690T (pt) | 2017-12-22 |
| RS56574B1 (sr) | 2018-02-28 |
| JP6189463B2 (ja) | 2017-08-30 |
| RU2013150330A (ru) | 2015-05-20 |
| JP6782281B2 (ja) | 2020-11-11 |
| JP2017200948A (ja) | 2017-11-09 |
| EP2696690A1 (en) | 2014-02-19 |
| EP2696690B1 (en) | 2017-10-04 |
| CY1119693T1 (el) | 2018-04-04 |
| JP2018145197A (ja) | 2018-09-20 |
| EP3292763A1 (en) | 2018-03-14 |
| HUE037452T2 (hu) | 2018-08-28 |
| JP2016155833A (ja) | 2016-09-01 |
| EP2696690A4 (en) | 2014-10-29 |
| NO2629082T3 (hr) | 2018-03-31 |
| JP2014513085A (ja) | 2014-05-29 |
| US20120265011A1 (en) | 2012-10-18 |
| SI2696690T1 (en) | 2018-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171853T1 (hr) | Sulfatne soli kao ubrzivači vremena prolaska | |
| Rohof et al. | An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease | |
| Yamamoto et al. | Clinical practice guideline for enteroscopy | |
| JP2017200948A5 (hr) | ||
| JP2013501224A5 (hr) | ||
| Niv et al. | Capsule endoscopy–comparison of two strategies of bowel preparation | |
| Tochetto et al. | CT enterography: concept, technique, and interpretation | |
| Ono et al. | Intraoperative localization of arteriovenous malformation of a jejunum with combined use of angiographic methods and indocyanine green injection: report of a new technique | |
| Frieling et al. | Prospective and randomized study to evaluate the clinical impact of cap assisted colonoscopy (CAC) | |
| Zhang et al. | Barium sulfate aspiration: severe chemical pneumonia induced by a massive reflux of contrast medium during small bowel barium enema | |
| Kalra et al. | Comparison of capsule endoscopy findings to subsequent double balloon enteroscopy: a dual center experience | |
| Fireman et al. | Future of capsule endoscopy | |
| Boriskin et al. | CT enterography vs. capsule endoscopy | |
| Inoue et al. | Spontaneous fistulization of infected walled-off pancreatic necrosis into the duodenum and colon. | |
| Hegde et al. | Esophagobronchial fistulae: Diagnosis by MDCT with oral contrast swallow examination of a benign and a malignant cause | |
| WO2012120027A1 (en) | Enema compositions | |
| Tsuji et al. | Serrated adenoma of the inverted vermiform appendix showing a gigantic pedunculated polyp-like appearance. | |
| Horton et al. | Acute gastrointestinal bleeding: the potential role of 64 MDCT and 3D imaging in the diagnosis | |
| Pehlivan et al. | Fatal aorto-esophageal fistula in child: a case report | |
| Ruiz-Rebollo | Should rectal retroflexion be included as a quality indicator for colonoscopy? | |
| Hajj-Chahine et al. | eComment. Late presentation of thoracic textiloma | |
| Santhosh et al. | Importance of diffuse versus focal F-18 fluoro-deoxy-glucose uptake in oesophagus | |
| Johnson | 76 Splenic artery aneurysm mimicking pancreatic neuroendocrine tumor | |
| Farraye et al. | Increase in Serrated Polyp Detection Rate Over Time in a Cohort of Average Risk Patients Undergoing Screening Colonoscopy: 471 | |
| Boyd-Carson et al. | PTU-051 Diagnostic yield of oesophago-gastro-duodenoscopy as the initial investigation for patients presenting with haematochezia |